Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2015 - 2026)

Corvus Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 64.32% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 64.32% YoY), while the FY2025 annual figure was $6.5 million, up 74.12% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.4 million, down from $6.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $8.6 million in Q3 2022, with the low at $589000.0 in Q1 2024.
• The 5-year median for Accumulated Expenses is $4.2 million (2024), against an average of $3.8 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 89.52% in 2024, then jumped 557.22% in 2025.
• Corvus Pharmaceuticals' Accumulated Expenses stood at $1.1 million in 2022, then tumbled by 38.54% to $684000.0 in 2023, then surged by 444.59% to $3.7 million in 2024, then jumped by 74.12% to $6.5 million in 2025, then slumped by 78.71% to $1.4 million in 2026.
• Business Quant data shows CRVS's Accumulated Expenses at $1.4 million in Q1 2026, $6.5 million in Q4 2025, and $715000.0 in Q3 2025.